Table 2. Bacitracin and neomycin susceptibility of MRSA USA300 and other MRSA isolates*.
Bacitracin/neomycin |
MRSA USA300 (MICs of bacitracin, neomycin, and polymyxin B)† | Other MRSA |
||
---|---|---|---|---|
Kyoto University Hospital |
Nagoya Medical Center |
ATCC type strains |
||
R/R | 9 (400, 128, 200–400) | 0 | BAA1717 (400, 128, 400) | 0 |
R/S | 0 | 1 (400, 0.25, 400) | 0 | |
S/R | 0 | 0 | 11 | |
I/S | 0 | 0 | 1 | |
S/I | 0 | 0 | 132 | |
S/S |
9 (6.25–12.5, 0.25, 400) |
0 |
BAA1556 (6.25, 0.25, 400) |
96 |
Total | 18 | 1 | 2 | 240 |
*MRSA, methicillin resistant Staphylococcus aureus; ATCC, American Type Culture Collection (Manassas, VA, USA); R, resistant; S, susceptible; I, intermediate resistance. †MICs are expressed as units/mL for bacitracin and polymyxin B and in μg/mL for neomycin.